3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
2
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Breast
1
Conditions
Ovarian Neoplasms
8
Uterine Cervical Neoplasms
5
Melanoma
5
Head and Neck Neoplasms
5
Urinary Bladder Neoplasms
4
Triple Negative Breast Neoplasms
4
Stomach Neoplasms
4
Neoplasms
4
Fallopian Tube Neoplasms
4
Colorectal Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Breast Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
3
Recurrence
3
Pancreatic Neoplasms
3
Neoplasm Metastasis
3
Endometrial Neoplasms
3
Prostatic Neoplasms
2
Kidney Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Merkel Cell
2
Carcinoma, Hepatocellular
2
Vulvar Neoplasms
1
Uveal Melanoma
1
Uterine Neoplasms
1
Thyroid Neoplasms
1
Skin Neoplasms
1
Sarcoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Interventions
utomilumab
1
tislelizumab
1
spartalizumab
1
entinostat
1
cemiplimab
1
Thrombopoietin
1
Polyethylene Glycols
1
Nivolumab
1
Immunologic Techniques
1
Ifosfamide
1
Granulocyte Colony-Stimulating Factor
1
Filgrastim
1
Etoposide
1
Cyclophosphamide
1
Carboplatin
1
Bevacizumab
1
ADI PEG20
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Uveal Melanoma
×
cemiplimab
×
Gynecologic
×
Clear all
NCT06022029
2025-12-24
ON-5001
OncoNano Medicine, Inc.
Phase 1
Recruiting
168 enrolled